

**Government of the District of Columbia
Department of Health**

**Prescription Drug Monitoring Program
Advisory Committee Meeting**

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

January 15, 2019

10:00am- 12:00 pm

OPEN SESSION AGENDA

CALL TO ORDER:

PRESIDING:

COMMITTEE MEMBERSHIP/ATTENDANCE:

ADVISORY COMMITTEE MEMBERS:		
	DR. JACQUELINE WATSON, DC HEALTH CHIEF OF STAFF (CHAIR)	
	MR. FRANK MEYERS, BOARD OF MEDICINE EXECUTIVE DIRECTOR	
	DR. SHAUNA WHITE, BOARD OF PHARMACY EXECUTIVE DIRECTOR	
	DR. NATALIE KIRILICHIN, EMERGENCY MEDICINE PHYSICIAN	
	COMMANDER JOHN HAINES, METROPOLITAN POLICE DEPARTMENT	
	MS. JESSICA DONALDSON, PHARMACY TECHNICIAN	
	MS. SHERI DOYLE, CONSUMER MEMBER	
STAFF:	TADESSA NICHOLS, PROGRAM SPECIALIST	
	LARNIQUE SUGICK, GRANT COORDINATOR	
	JOY ECKERT, PUBLIC HEALTH ANALYST	
	OLAMIDE IYANDA, MEDIA SPECIALIST	
LEGAL STAFF:	MS. CARLA WILLIAMS, ESQ, ASSISTANT GENERAL COUNSEL	
VISITORS:		

Open Session Agenda

Introduction:		
0115-O-01	<p><u>Welcome & Introductions</u></p> <p><u>Charge of the Committee</u></p> <p>The Committee shall convene at least two (2) times per year to advise the Director:</p> <ul style="list-style-type: none">(a) On the implementation and evaluation of the Program;(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and(f) Regarding the design and implementation of educational courses for:<ul style="list-style-type: none">(1) Persons who are authorized to access the prescription monitoring information;(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.	
0115-O-02	<p><u>Approval of October 2018 PDMP Advisory Committee Meeting Minutes</u></p> <ul style="list-style-type: none">(a) Minutes from October 24, 2018 Meeting	

0115-O-03	<u>2018 PDMP Advisory Committee Year in Review</u>	
0115-O-04	<u>DC Opioid Strategic Plan (Live. Long. DC)</u> (a) Washington Post- Opioid Epidemic Video	
0115-O-05	<u>Report from Attorney Advisor</u> (a) PDMP Legislative Update (b) Update: Gabapentin to be added as drug of concern	
0115-O-06	<u>Program Updates</u> (a) Program Statistics (b) Past and Future Outreach Activities (c) PDMP Annual Report (d) PDMP Best Practice Checklist updates and discussion	
0115-O-07	<u>Grant Updates</u> (a) Statewide Gateway Integration (b) Professional License Integration (c) Opioid Indicator Dashboard (d) Opioid Awareness Communications Campaign	
0115-O-08 Matters for Consideration	<u>Action Items</u> <ul style="list-style-type: none"> • Future meeting dates: <ul style="list-style-type: none"> - April 25th, 2019 - July 16th, 2019 - October 15th, 2019 	
0115-O-09	<ul style="list-style-type: none"> • Other news/highlights from Committee members 	
Comments from the Public		
Motion to Adjourn the Open Session	Madam Chair, I move that the Committee close the Open Public session portion of the meeting. (Roll Call Vote)	

This concludes the Public Open Session of the meeting.

Open Session Meeting Adjourned at __: __ PM